US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
WO1981001145A1
(en)
|
1979-10-18 |
1981-04-30 |
Univ Illinois |
Hydrolytic enzyme-activatible pro-drugs
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
JPS63502716A
(ja)
|
1986-03-07 |
1988-10-13 |
マサチューセッツ・インステチュート・オブ・テクノロジー |
糖タンパク安定性の強化方法
|
US4861719A
(en)
|
1986-04-25 |
1989-08-29 |
Fred Hutchinson Cancer Research Center |
DNA constructs for retrovirus packaging cell lines
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
GB8705477D0
(en)
|
1987-03-09 |
1987-04-15 |
Carlton Med Prod |
Drug delivery systems
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
US5204244A
(en)
|
1987-10-27 |
1993-04-20 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
US5202238A
(en)
|
1987-10-27 |
1993-04-13 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
US5278056A
(en)
|
1988-02-05 |
1994-01-11 |
The Trustees Of Columbia University In The City Of New York |
Retroviral packaging cell lines and process of using same
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5670488A
(en)
|
1992-12-03 |
1997-09-23 |
Genzyme Corporation |
Adenovirus vector for gene therapy
|
NZ258392A
(en)
|
1992-11-13 |
1997-09-22 |
Idec Pharma Corp |
Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
|
EP0689601B1
(en)
|
1993-02-22 |
2006-10-04 |
The Rockefeller University |
Production of high titer helper-free retroviruses by transient transfection
|
FR2712812B1
(fr)
|
1993-11-23 |
1996-02-09 |
Centre Nat Rech Scient |
Composition pour la production de produits thérapeutiques in vivo.
|
IL116816A
(en)
|
1995-01-20 |
2003-05-29 |
Rhone Poulenc Rorer Sa |
Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
AU690474B2
(en)
|
1995-09-11 |
1998-04-23 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody againts alpha-chain of human interleukin 5 receptor
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
DE60040556D1
(de)
|
1999-12-06 |
2008-11-27 |
Univ Illinois |
Hochaffine t-zellrezeptorproteine und verfahren
|
DE10225139A1
(de)
|
2002-05-29 |
2004-02-26 |
Immatics Biotechnologies Gmbh |
Verfahren zur Identifizierung von immunreaktiven Peptiden
|
CA2505558C
(en)
|
2002-11-09 |
2013-07-02 |
Avidex Limited |
T cell receptor display
|
GB0308731D0
(en)
|
2003-04-15 |
2003-05-21 |
Anticancer Therapeutic Inv Sa |
Method of radiotherapy
|
US7811828B2
(en)
|
2004-01-28 |
2010-10-12 |
Immatics Biotechnologies Gmbh |
Method for identifying and quantifying of tumuor-associated
|
NO2195023T3
(pt)
|
2007-08-29 |
2018-08-04 |
|
|
US9840695B2
(en)
|
2009-04-28 |
2017-12-12 |
Agriculture Victoria Services Pty Ltd |
Plant technology
|
GB201006360D0
(en)
|
2010-04-16 |
2010-06-02 |
Immatics Biotechnologies Gmbh |
Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
|
TWI588156B
(zh)
|
2011-03-28 |
2017-06-21 |
賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
EP2970484B2
(en)
|
2013-03-15 |
2022-09-21 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
GB201423361D0
(en)
|
2014-12-30 |
2015-02-11 |
Immatics Biotechnologies Gmbh |
Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
|
CN107428835B
(zh)
|
2015-01-23 |
2021-11-26 |
赛诺菲 |
抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
|
GB201504502D0
(en)
|
2015-03-17 |
2015-04-29 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
|
GB201505305D0
(en)
|
2015-03-27 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel Peptides and combination of peptides for use in immunotherapy against various tumors
|
GB201505585D0
(en)
|
2015-03-31 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
|
GB201507719D0
(en)
|
2015-05-06 |
2015-06-17 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
|
GB201510771D0
(en)
|
2015-06-19 |
2015-08-05 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
|
GB201511191D0
(en)
|
2015-06-25 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
T-cell epitopes for the immunotherapy of myeloma
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
GB201511792D0
(en)
|
2015-07-06 |
2015-08-19 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
|
GB201512369D0
(en)
|
2015-07-15 |
2015-08-19 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
US20170136108A1
(en)
|
2015-08-28 |
2017-05-18 |
Immatics Biotechnologies Gmbh |
Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
|
GB201517538D0
(en)
|
2015-10-05 |
2015-11-18 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
|
MA45004A
(fr)
|
2015-10-09 |
2019-03-27 |
Immatics Biotechnologies Gmbh |
Anticorps spécifiques anti-wt1-hla
|
GB201521746D0
(en)
|
2015-12-10 |
2016-01-27 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
|
GB201521894D0
(en)
|
2015-12-11 |
2016-01-27 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against various cancers
|
GB201522667D0
(en)
|
2015-12-22 |
2016-02-03 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
|
GB201602918D0
(en)
|
2016-02-19 |
2016-04-06 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
|
GB201603568D0
(en)
|
2016-03-01 |
2016-04-13 |
Immatics Biotechnologies Gmbh |
Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
|
GB201603987D0
(en)
|
2016-03-08 |
2016-04-20 |
Immatics Biotechnologies Gmbh |
Uterine cancer treatments
|
GB201604494D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
|
GB201604492D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
|
DE102016115246C5
(de)
|
2016-08-17 |
2018-12-20 |
Immatics Biotechnologies Gmbh |
Neue t-zellrezeptoren und deren verwendung in immuntherapie
|
DE102016123847B3
(de)
|
2016-12-08 |
2018-04-05 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
|
DE102016123859B3
(de)
|
2016-12-08 |
2018-03-01 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
|
DE102017106305A1
(de)
|
2017-03-23 |
2018-09-27 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
|
DE102017114737A1
(de)
|
2017-06-30 |
2019-01-03 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
|
WO2019012141A1
(en)
*
|
2017-07-14 |
2019-01-17 |
Immatics Biotechnologies Gmbh |
IMPROVED POLYPEPTIDE MOLECULE WITH DOUBLE SPECIFICITY
|
DE102018100967B4
(de)
|
2018-01-17 |
2019-08-14 |
Immatics US, Inc. |
Verfahren zur feststellung der wirksamkeit von viralen vektoren
|